atai Life Sciences’ Post

View organization page for atai Life Sciences, graphic

26,662 followers

An estimated 3 million people in the US suffer from Opioid Use Disorder (OUD).   OUD and addiction, in general, are notoriously difficult to treat, with most current treatments inadequately addressing patients’ symptoms, and often leading to relapse.   At atai, we are committed to pioneering new treatment options for those suffering from the most challenging mental health conditions. We’re conducting a clinical program with ibogaine, IBX-210, for the treatment of OUD. Ibogaine has shown promising potential in reducing opioid cravings and supporting withdrawal symptoms in previous clinical studies. You can follow the progress of this program and our other clinical programs by visiting our website and signing up for email updates. https://atai.life/   Special thanks to Heather McKenzie at BioSpace for raising this important topic and covering our research. Read more: https://lnkd.in/eVMb-e7i   #Ibogaine #OpioidCrisis #AddictionTreatment #MentalHealth 

Psychedelic Therapies Could Soon Break Through Against Addiction | BioSpace

Psychedelic Therapies Could Soon Break Through Against Addiction | BioSpace

biospace.com

Cynthia Hunefeld

CEO & Founder Evithé Biotechnology

1mo

Good to see the Ibogaine research move forward. Is the Radboud University still involved in this work these days?

Like
Reply

To view or add a comment, sign in

Explore topics